View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 17, 2017

Interface Clinical Research develops new GP model to minimise clinical trial drop outs

Interface Clinical Services’ division Interface Clinical Research has developed a new model to decrease the number of patient dropouts from clinical trials.

Interface Clinical Services’ division Interface Clinical Research has developed a new model to decrease the number of patient dropouts from clinical trials.

The new model will conduct Phase III and IV primary care clinical trials in existing general practitioner (GP) facilities across the UK, and enrol patients from the practice’s existing database.

Interface’s GCP-trained pharmacists will perform an advanced database screen to identify the ideal subjects.

According to CenterWatch, 58% of subjects decline consent for a trial, 32% fail the screening and 18% drop out after enrolment.

The new recruitment approach is expected to result in fewer failures during the clinical trial screening and reduced dropouts, as the subjects will not have to travel long distances to a particular clinical site.

"Interface has identified more than 40 GP practices and healthcare organisations that are willing to join its model for conducting the trials."

The familiarity with the facilities and staff at the local practice was also found to aid the decrease in dropouts post enrolment.

It was also demonstrated that as patients will be seen on time at the local practice by an investigator from Interface, there is less chance for the decline of consent.

The new model is designed to address standard recruitment and trial procedure concerns such as fixed cost of the dedicated research centre and limited access to large patient databases.

While individual GP models were not successful due to a heavy workload, the new integrated model is expected to result in an effective retention of subjects.

Interface has identified more than 40 GP practices and healthcare organisations that are willing to join its model for conducting the trials.

The company is currently performing large-scale feasibility studies using the combined GP databases.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena